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Abstract:  There is a vast amount of literature related to mouse liver tumorigenesis generated over the past 60 years,
not all of which has been captured here.  The studies reported in this literature have generally been state of the art at
the time they were carried out.  A PubMed search on the topic “mouse liver tumors” covering the past 10 years yields
over 7000 scientific papers.  This review address several important topics related to the unresolved controversy regarding
the relevance of mouse liver tumor responses observed in cancer bioassays.  The inherent mouse strain differential
sensitivities to hepatocarcinogenesis largely parallel the strain susceptibility to chemically induced liver neoplasia.  The
effects of phenobarbital and halogenated hydrocarbons in mouse hepatocarcinogenesis have been summarized because
of recurring interest and numerous publications on these topics.  No single simple paradigm fully explains differential
mouse strain responses, which can vary more than 50-fold among inbred strains.  In addition to inherent genetics,
modifying factors including cell cycle balance, enzyme induction, DNA methylation, oncogenes and suppressor genes,
diet, and intercellular communication influence susceptibility to spontaneous and induced mouse hepatocarcinogenesis.
Comments are offered on the evaluation, interpretation, and relevance of mouse liver tumor responses in the context of
cancer bioassays.   (J Toxicol Pathol 2009; 22: 11–33)
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Introduction
Since the early 1970s and even before, the mouse liver
tumor response observed in cancer bioassays has been a
source of unresolved controversy with books, symposia, and
advisory committee deliberations on the topic1–8.  Some
have taken the debate further and argued that the mouse
bioassay should be eliminated altogether from our hazard
identification/safety assessment armamentarium and that a
one species default model, the rat, is sufficient9.  Debates on
a one or two species bioassay and the relevance of the mouse
liver tumor response continue.
Our knowledge of factors associated with mouse
hepatocarcinogenesis has significantly improved over the
last two decades.  The diagnostic and nomenclature issues of
concern in the 1970’s have been largely resolved.  The
propensity of male mice versus females to develop
spontaneous and treatment-induced liver tumors is better
understood.  Advances in the genetics of strain susceptibility
have been made, although more work remains to tease out
the definitive genes responsible.  Modulators of murine
hepatocarcinogenesis, such as diet, hormones, oncogenes,
methylation, imprinting, and cell proliferation/apoptosis are
among multiple mechanistically associated factors that
impact this target organ response in control as well as treated
mice.  With the advancement of our understanding, it has
become obvious that no mode of action, pathway, or
mechanism should be considered mutually exclusive.
There is no one simple paradigm to explain the
differential strain sensitivity to hepatocarcinogenesis.  With
the recent effort to delineate over 8 million single nucleotide
polymorphisms in 15 mouse strains selected for genetic re-
sequencing10, the prospect for continued and possibly
specialized use of mice for hazard identification and safety
assessment remains.  In the meantime, we need to continue
ongoing efforts and progress in defining threshold limiting
factors that impact murine hepatocarcinogenesis and use this
knowledge to place the mouse liver tumor response in
appropriate regulatory perspective.  There will always be a
need for research on mode of action and quantitative
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differences/similarities between species.
Origins of Inbred Mice
Classical strains used in research today were originally
derived from interbreeding of Mus musculus subspecies.  It
first started as a hobby in 18th century Victorian England and
Asia with breeding of “fancy” mice based on coat color and
the subsequent adoption of some of these mice in the early
1900’s by researchers in the United States10–13.  The oldest
inbred strain, the DBA/2 (originally dba for d = dilute, b =
brown, and a = non-agouti) was established in 1909 by C. C.
Little14.  Ten years later the mouse lady of Granby,
Massachusetts, Miss Abbie E. C. Lathrop, intercrossed black
offspring of a female 57 mouse to produce a stock of mice
ultimately used by Clarence Cook Little to form his C line
resulting in the C57BL/612,13.  Strains A, C3H, and CBA
were created by Leonell C. Strong in the early 1940’s15.
Commonly used mouse strains
In the early 1960’s the National Cancer Institute
adopted the B6C3F1 mouse, the F1 hybrid of the C57BL/6
female and C3H male, as the mouse for use in the cancer
bioassay program.  The decision to use the B6C3F1 mouse
was based on results from an 18-month study involving
20,000 mice including two hybrid lines and 127 different
chemicals16.  Partially based on historic inertia and partly
based on a concern about losing the historic control database,
the B6C3F1 has remained the mouse model of choice in U.S.
Government-sponsored hazard identification programs for
toxicity and cancer.  Variations of the C57BL and the
outbred Swiss stock are popular models for safety
assessment by the chemical and pharmaceutical industries
while these plus the A strain, B6CF1, C3H, BALB/c, FVB,
129, and others are used by biomedical researchers.  The
recent publication of mouse haplotype maps for 15 inbred
mouse strains, including 8 classical strains commonly used
for research, is expected to facilitate obtaining important
information for a wide range of biological questions10 and
may influence how mice are used for hazard identification in
the future.
Experimental Protocols/Models for Mouse Liver
Tumor Induction
Conventional hazard identification bioassay
While the hazard identification paradigm of
maintaining a core group of 50 animals per dose per sex has
remained relatively constant for many years, modifications
such as include three to five doses, some of which
approximate human exposure levels, in utero exposures and
stop studies have been added to answer specific questions.
The basic hazard identification study commences exposures
when mice and rats are 6 to 8 weeks of age and treatment
typically continues for 2 years.  When using specifically
susceptible mouse strains such as the B6C3F1 hybrid,
relatively high and variable incidences of liver tumors can
occur in the untreated or vehicle control mice.  The liver
tumor incidence increases as the mice age with the majority
of liver tumors occurring after 20 months of age17.
Single or multiple doses to adult mice
Administration of a few to several repeated doses of
known and usually genotoxic hepatocarcinogens, starting
with 5 to 8-week old mice will yield liver tumors in a few
months, making this a potentially useful tool to follow liver
tumor pathogenesis and to study variables that might
influence hepatocarcinogenesis.  Published reports using this
type of protocol were fairly common prior to the 1970s with
a general switch to initiation-promotion studies in
subsequent years.  It should be noted, however, that repeated
and prolonged exposures to nongenotoxic agents certainly
can result in induction of mouse liver tumors.
Neonatal mouse model
While variations of this model have been used, the
basic approach is to administer one to three doses of the test
agent prior to weaning with no further treatment.  The
rationale is that “fixation” of hepatocellular initiation will be
favored by the high rate of cell growth during the neonatal
period.  Subsequent endogenous promotion would allow for
clonal expansion of any initiated clones with development of
liver tumors within a 12-month observation period.  This
model, using either CD1 or B6C3F1 mice, has been
described and shown to work well with genotoxic test
agents18.  A single dose of a hepatocarcinogen such as
diethylnitrosamine to a neonate at 12 to 15 days of age will
yield a high incidence and multiplicity of liver neoplasia
with a relatively short latency while the same dose given to
the adult mouse will result in a lower incidence and
multiplicity with a much longer latency period.  B6C3F1 and
C3AF1 mice neonatally treated with ethylnitrosourea versus
treatment at 42 days of age results in a 3- to 8-fold increase
in liver tumors in the neonates compared to the older dosed
mice19.  This age difference is based upon an efficient
initiation of hepatocytes during the neonatal period when
there is rapid liver growth20–22.  The neonatal mouse model
has been used extensively to learn more about the biology of
murine hepatocarcinogenesis and has included studies on the
genetics of susceptibility, the relative roles of cell
proliferation and apoptosis, effects of hormones and diets on
liver tumor development, and the effects of DNA
methylation on expression of genes relevant to murine
hepatocarcinogenesis.
Initiation-promotion protocols
These protocols typically consist of administration of
the initiating agent, usually diethylnitrosamine, to either
neonatal mice or to mice shortly after weaning followed by
repeated dosing with an agent being tested as a liver tumor
promoter.  One variation involves administration of a
necrogenic dose of diethylnitrosamine 1 to 2 weeks after
weaning.  Another variation involves partial hepatectomy of
5 to 6 week old mice followed in 36 hours by a non-Maronpot 13
necrogenic dose of diethylnitrosamine23.  These two
protocols without further treatment will generally yield 3 or
more liver tumors per mouse at one year of age.  A third
protocol, the preweaning initiation-promotion protocol,
involves administration of a non-necrogenic dose of
diethylnitrosamine or an alternative initiator often at age day
12 or 15 followed by administering the agent being tested for
promotion shortly after weaning.  Without further treatment,
these mice can develop a high multiplicity of liver tumors by
one year of age while treatment with a promoter significantly
shortens the time to tumor.  Partial hepatectomy alone after
preweaning initiation also serves as a liver tumor promoter24.
While these initiation-promotion protocols can be carried out
until there is an obvious liver tumor endpoint, quantitation of
putative preneoplastic foci of cellular alteration has been
used as a biomarker of hepatocarcinogenicity.  Features of
these initiation-promotion protocols have been described in a
review paper dealing with phenobarbital promotion25.  There
are variations such as initiation by treatment with
diethylnitrosamine in drinking water for 4 weeks followed
by promotion26 and other examples will be referenced
throughout this document.
Genetically engineered mouse models
Several lines of viral oncogene induced mouse models
of hepatic neoplasia are summarized by Sandgren27,28.  These
include ras and myc oncogenes under the influence of the
albumin gene regulatory elements29,30 as well as SV40-TAg
driven by a variety of regulatory elements27,31.  Growth
factors such as TGFalpha and IGF2 under the influence of
the metallothionein-1 or major urinary protein regulatory
elements, respectively, yield dysplastic foci in as little as 6
months and hepatocellular neoplasms in 8 to 18 months27,32
with evidence of severe hepatic dysplasia in newborn mice33.
In an effort to more closely mimic human hepatitis-
associated hepatocellular neoplasia, a small number of
genetically engineered mouse models based on
incorporation of various portions of the human hepatitis
virus such as the HB × gene and the pre-S2 gene have been
developed34,35 and show a male predominance under the
influence of androgens and glucocorticoids36.  Hepatic
changes can appear as early as 4 weeks and consist of
glycogen-rich centrilobular foci of cellular alteration37,38.
During a latent period of several months the altered foci
show enhanced cell proliferation and aneuploidy with
ultimate development of hepatocellular carcinomas adjacent
to adenomas and additional foci of cellular alteration.  The
yield of hepatocellular carcinomas can exceed 80%39 and an
X gene/c-myc construct will yield dysplastic foci in 12
weeks and hepatocellular carcinomas between 20 and 28
weeks40.  In essentially all of the HBV models of HCC, there
is an imbalance of cell proliferation and apoptosis34,41.
B6C3F1 mice expressing genotype 1a hepatitis C virus
core and envelope proteins 1 and 2 develop hepatopathy and
are prone to lymphoid neoplasia as well as heptocellular
carcinoma42.  Lymphoid neoplasia was seen after age 18
months.  Hepatopathy was present at 12 months and tumors
later (exact age of occurrence of hepatocellular carcinomas
not stated).
The genetically engineered mouse models that have
been proposed for hazard identification, such as the rasH2
and p53+/-, fall into the category of hepatocarcinogenesis
resistant mice.
Strain Susceptibility to Spontaneous and Induced
Liver Tumors: Biology
Based on genetic and numerous other factors, mouse
stocks and inbred strains differ in susceptibility to both
spontaneous and treatment-induced liver neoplasia.  Because
of the variety of studies with differing protocols used to
generate susceptibility data, direct comparisons among
strains and stocks is problematic and, in looking across the
numerous published studies, the best we can do is to classify
mice by their relative susceptibility to hepatocarcinogenesis.
By way of example, CBA and C3H inbred mice are
considered highly susceptible to induction of liver neoplasia
while in comparison C57BL/6 and BALB/c are relatively
resistant43.
There are two metrics typically used to categorize liver
tumor susceptibility: incidence and multiplicity.  The former
is most often used to characterize spontaneous liver
neoplasia and the latter to assign relative susceptibility to
treatment-induced liver neoplasia.  A study by Hanigan and
co-workers serves to demonstrate the magnitude of relative
susceptibility.  Utilizing an identical protocol, a direct
comparison between C3H/HeJ and C57BL/6J male mice
with respect to liver tumor induction demonstrated up to a
40-fold difference in liver tumor multiplicity20.
In defining resistance and susceptibility (i.e., strain
dependent variablilty), two factors play a significant role
– the number of initiated tumor cells and the rate of
tumor growth.  Using the basal levels as an indicator of
potential spontaneous initiation in mouse liver, 8-
hydroxydeoxyguanosine (OH8dG) strain differences in
C3H, B6C3F1, and C57BL mice are positively correlated
with spontaneous hepatocellular neoplasia44.  Since
formation of OH8dG has been shown to result in gene
mutation45 and hypomethylation46, it may also contribute via
these mechanisms to the differential strain susceptibility to
spontaneous hepatocarcinogenesis.  C3H mice are more
susceptible than C57BL/6 mice to a variety of
hepatocarcinogens with differing metabolic activation
patterns and they form similar numbers of preneoplastic
lesions and DNA adducts47,48, indicating that the relative
susceptibility of these mice is based on detection of
proliferative lesions which in turn is dependent upon lesion
growth rate within the temporal context of the experimental
study.
Spontaneous liver tumors
The strain-specific spontaneous incidence of liver
tumors (originally diagnosed as hepatomas) in mice has been
documented in the published literature since the late 1930’s14 Mouse Hepatocarcinogenesis
and early 1940’s.  Andervont reported on the occurrence of
spontaneous hepatomas in C3H mice49,50, with Burns and
Schenken publishing in the following year51.  Subsequent
reports of C3H sublines maintained in different laboratories
and over time have confirmed the high spontaneous
incidence of liver tumors52,53.  The high susceptibility of
CBA mice was noted in 193654 and has since been confirmed
by others53,55–57.
Data on tumor incidences including liver tumors for
other strains and various F1 hybrids have been published
(LP, 129, DBA/2, C57BL/10 -57; BALB/c, C57BL/6-58).
These studies confirm the low incidence of spontaneous
hepatocellular neoplasia in LP, 129, DBA/2, BALB/c, and
C57BL mice.
Attempts at comparative tabulation of the incidences in
these reports of spontaneous liver tumor incidence among
different mouse strains can be potentially misleading since
countless variables including study design, diet, caging,
diagnostic features, and study duration differ among these
reports.
Treatment induced liver tumors
Strain sensitivity to treatment induced liver tumors
generally parallels strain susceptibility to spontaneous liver
tumor development23,48,59–62.  Susceptibility to treatment-
induced liver neoplasia is contingent upon the temporal
timing and frequency of dosing as well as the magnitude of
the dose and the duration of the study observation period.
Thus, a single dose of a hepatocarcinogen such as
diethylnitrosamine to a neonate at 15 days of age will yield
a high incidence and multiplicity of liver neoplasia with a
short latency while the same dose given to the adult mouse
will result in a lower incidence and multiplicity with a
much longer latency period.  A 10-fold increase in
diethylnitrosamine (5 to 50 mg/kg) resulted in a 3.7-fold
increase in number of tumors but with size distribution
similar at the low and high dose63.  Swiss mice initiated
neonatally with ethylnitrosourea at two different doses also
had a dose-dependent increase in liver tumors64 as did
B6C3F1 mice initiated with dimethylnitrosamine65, and
BALB/c mice treated with 2-acetylaminofluorene66.  It was
also reported that the higher doses favored the development
of malignant over benign liver tumors58,65.
The number of papers dealing with treatment-induced
hepatocarcinogenesis and the various treatment regimens are
legion.  A few illustrative examples to highlight strain
susceptibility will be provided.
The sensitivity of C3H mice to chemical induction of
liver tumors began to be documented shortly after their
susceptibility to spontaneous liver tumors was known.
Heston and coworkers showed increased susceptibility to
liver tumors in C3H mice treated with urethane53 and the
antifertility drug enovid67.  In more recent years, studies
at the McArdle lab by Drinkwater and coworkers as well
as in the laboratory of Dragani and coworkers in Milan
have studied the genetics and modifying factors
responsible for differential strain sensitivity to murine
hepatocarcinogenesis.
Using a neonatal mouse model in which the mice were
injected no later than 16 hours after birth, it was shown that
9, 10-dimethyl-1,2-benzanthracene caused a pronounced
increased incidence of liver tumors in male and female C3H,
CBA, C3H × CBA, and CBA × C3H but only a marginal
increase in strain A, C57BL, A × C57BL, C57BL × A,
BALB/c and IF68.  Liver tumor latency was the shortest in
male C3H mice.
Both diethylnitrosamine and ethylnitrosourea have
been used in studies of treatment-induced mouse
hepatocarcinogenesis.  Vesselinovitch published several
studies in the 1970s primarily using the B6C3F1 preweaning
initiation-promotion mouse model with ethylnitrosourea19,69–
71.  Lee used this model to study diethylnitrosamine induced
liver tumors in C3H–C57BL/6 chimeras72.  A comparison of
11 inbred strains using ethylnitrosourea and/or
diethylnitrosamine was reported by the McArdle lab73.
While treated males typically are more susceptible to
liver tumor induction than treated females, occasional
exceptions do occur.  Male and female C3H mice treated
with carbon tetrachloride by gavage and 4-o-tolylazo-o-
toluidine by subcutaneous injection develop increased
incidences of hepatomas with the female response to 4-o-
tolylazo-o-toluidine exceeding that of the treated males74.
Another example of a prominent female response is seen In
diethylnitrosamine treated C57BR/cdJ mice75.
DBA/2 susceptibility
Male DBA/2 mice represent an unusual and puzzling
situation with respect to liver tumor susceptibility.  The
spontaneous liver tumor rate is a low 1.5%57 and treatment of
5-week-old male DBA/2 mice with diethylnitrosamine
yields a relatively low liver tumor response60.  However,
treatment of 12-day old DBA/2 mice with
diethylnitrosamine results in a 20-fold increase in liver
tumor multiplicity versus liver tumor multiplicity in the
resistant C57BL/6 mouse76,77.  The reason for this
differential in susceptibility is not known but differences in
metabolism have been speculated as playing a role60.
Two specific categories of treatment induced murine
liver tumors, viz., halogenated hydrocarbons and
phenobarbital, are highlighted separately because of general
academic and regulatory interest.
Halogenated hydrocarbons
Halogenated hydrocarbons continue to receive
scientific attention because of potential widespread human
exposure to contaminated drinking water as well as to water
disinfection by-products.  This class of compounds is clearly
associated with liver tumor induction in mice and typically
there is no clear evidence of carcinogenicity in other species,
including rats.  There are multiple modes of action believed
to be contributory to the murine hepatocarcinogenicity
associated with one or more of the halogenated
hydrocarbons.  These include enhanced cell proliferation,
decreased apoptosis, perturbation of DNA methylation,Maronpot 15
disruption of gap junctional intercellular communication,
activation of oncogenes, and peroxisome proliferation.
Often used as a classic example of the enhanced cell
proliferation secondary to a cytotoxicity mode of action,
chloroform has been classified as possibly carcinogenic to
humans (IARC Classification 2B).  While corn oil gavage of
chloroform leads to murine liver tumors in B6C3F1 male
and female mice78, chloroform given in drinking water is not
hepatocarcinogenic79,80.  This differences is attributed to
differential hepatotoxicity and increased hepatocellular
proliferation in gavage studies79,81.  Similarly, when
chloroform was given by drinking water in an initiation-
promotion study, it inhibited liver tumor development
compared with a positive liver tumor response with
phenobarbital promotion26.  Cytotoxicity and secondary
enhanced cell proliferation has been proposed as a primary
mode of action for three other trihalomethanes
(bromodichloromethane, chlorodibromomethane, and
bromoform)82.
The mode of action of the murine hepatocarcinogen
trichloroethylene is extensively reviewed by Bull83.
Trichloroethylene causes liver tumors in B6C3F1 and Swiss
mice.  The metabolism of trichloroethylene to chloral
hydrate, dichloroacetic acid, and trichloroacetic acid
complicates teasing out the modes of action since these
metabolites are also hepatocarcinogenic in mice83.
Modification of cell signaling pathways that alter cell
replication and cell death as a consequence of decreased
DNA methylation as well as c-myc and c-jun methylation are
likely contributory modes of action for the tumorigenic
effects of trichloroethylene83,84.  Studies of the
trichloroethylene metabolites dichloroacetic acid,
trichloroacetic acid, and chloral hydrate suggest that both
dichloroacetic acid and trichloroacetic acid are involved in
trichloroethylene-induced liver tumorigenesis and that many
dichloroacetic acid effects are consistent with conditions that
increase the risk of liver cancer in humans85.  Some of these
effects involve GST Xi, histone methylation, and
overexpression of IGF285.
While there are differences in the type of dose response
for dichloroacetic acid and trichloroacetic acid induced
mouse liver tumors86, both dichloroacetic acid and
trichloroacetic acid have caused liver tumors in multiple
mouse studies87–89.  Several studies have examined the
modes of action involved in dichloroacetic acid induced
murine hepatocarcinogenesis and have implicated
hypomethylation90–92, enhanced cell proliferation90,
peroxisome proliferation or even activation of PPAR
without evidence of peroxisome proliferation89,93,94, and
oncogene activation84.  Based upon hypomethylation
identified in mouse liver tumors following initiation with
methylnitrosourea and promotion by dichloroacetic acid or
trichloroacetic acid, and as an early response in short term
exposure to dichloroacetic acid and trichloroacetic acid,
hypomethylation is clearly involved in murine
hepatocarcinogenesis associated with these
chemicals82,84,95,96 and can be blocked by dietary
methionine97.
A comprehensive review of aldrin/dieldrin has been
published98.  Dieldrin is considered a ground water
contaminant and, like the water disinfection by-products
discussed above, it is associated with mouse liver tumor
responses in different mouse strains99–101.  Oxidative stress
generated via futile cycling of the cytochromes enzymes has
been implicated as a primary mode of action responsible for
the murine liver tumor response98.  It has been proposed that
the consequences of oxidative stress are threshold responses
and should be used in risk assessment for dieldrin and for
other halogenated hydrocarbons98.
In addition to dieldrin, the organochlorine class of
chemicals has been clearly associated with induction of
murine liver tumors102.  Thirty-seven of 138 organochlorine
agrochemicals were hepatocarcinogenic in mice without an
apparent effect of mouse strain or study duration103.  A clear
positive association between hepatomegaly at one year and a
liver tumor response at 18 or 24 months was documented in
these studies.
Phenobarbital
Phenobarbital is one of the most widely studied rodent
hepatocarcinogens, is considered the prototype chemical for
a mode of action whereby hepatic enzyme induction leads to
rat and mouse liver tumor induction, and is typically used as
a positive control in rodent initiation-promotion protocols.
An extensive review of the relationship between
phenobarbital and mouse liver neoplasia has been published
by McClain104.  McClain provides information on a series of
studies utilizing different phenobarbital treatment protocols
from the early 1970s to the early 1980s to test for liver tumor
susceptibility in C3H, CF1, B6C3F1, and C57BL mice.  As
more studies have been carried out from the early 1970s to
the present time, it has become obvious that many different
factors and variables contribute significantly to
phenobarbital induced liver tumors.  For example,
depending upon the study protocol, phenobarbital may
enhance or inhibit liver tumor formation following
diethylnitrosamine initiation.  Diethylnitrosamine initiation
in the postweaning period versus diethylnitrosamine
initiation in the preweaning period results in enhancement or
inhibition of phenobarbital induced liver tumors,
respectively.  This paradoxical effect has been carefully
studied25.  The different effect on promotion may be a
reflection of the observation that phenobarbital enhances the
growth of eosinophilic but not basophilic foci of cellular
alteration and proportionally fewer eosinophilic foci are
produced with preweaning diethylnitrosamine initiation.
Most studies of the factors involved in phenobarbital
associated murine hepatocarcinogenesis have been carried
out utilizing initiation-promotion protocols.  These studies
include examination of differential strain sensitivity,
influence of phenobarbital on cell proliferation, oncogene
analysis in liver tumors, and effects of phenobarbital on
global DNA methylation as well as on methylation of
oncogenes.  Most of these studies have utilized the16 Mouse Hepatocarcinogenesis
preweaning neonatal model of initiation followed by
different promotion regimens.  The response in these studies
is dependent on the strain of mouse used and on the
initiating chemical carcinogen105.  C3H initiated with
diethylnitrosamine and given phenobarbital demonstrated
an increase in adenomas compared to diethylnitrosamine
treatment alone while B6C3F1 males had a decrease in
adenomas as a result of phenobarbital treatment.
Phenobarbital had no effect on hepatocellular adenomas in
C57BL/6 males previously treated with diethylnitrosamine.
Following 9, 10-dimethyl-1,2-benzanthracene initiation,
phenobarbital increased adenomas in both C3H and
B6C3F1 but not in C57BL mice.
In BALB/c mice phenobarbital treatment following
initiation by diethylnitrosamine resulted in a decrease
latency for heptic adenomas and an increased incidence of
adenomas at multiple sampling times106.
In comparing C57BL/6, C3H/HeN, and DBA/2 mice
initiated with diethylnitrosamine and treated for 17 weeks
with phenobarbital, Diwan and coworkers identified an
increase in preneoplastic foci and liver tumors in C3H and
DBA/2 mice but not in C57BL mice and noted that the DBA/
2 mice were especially responsive60.  In a different study
using reciprocal C57BL/6 and DBA/2 hybrids, susceptibility
to phenobarbital induced tumors was a dominant trait with
both F1 hybrids responding similarly107.
Timing of phenobarbital dosing appears to be important
in how mice respond to diethylnitrosamine initiation and
subsequent promotion by phenobarbital.  Diethylnitrosamine
alone induced focal hepatic lesions, adenomas and
carcinomas in B6C3F1 mice but subsequent treatment with
phenobarbital suppressed the effect of the
diethylnitrosamine, possibly due to some feminizing effect
of perinatal administration of phenobarbital108.
Diethylnitrosamine initiation at 6 and 10 weeks of age versus
initiation at 15 days of age with both followed by long-term
treatment with phenobarbital resulted in strong liver tumor
promotion following initiation at 6 and 10 weeks of age and
inhibition of liver tumor development following neonatal
initiation in B6C3F1 males109.  On the other hand, neonatal
initiation followed by phenobarbital promotion in BALB/c
males enhanced development of liver tumors109.  Similar
effects on inhibition of tumor development by phenobarbital
have been seen in B6C3F1 initiated with diethylnitrosamine
followed by phenobarbital promotion commencing at 4
weeks of age110.
There is considerable evidence to support the
differential strain susceptibility to phenobarbital induced
murine hepatocarcinogenesis.  Diethylnitrosamine injection
followed by partial hepatectomy and subsequent dietary
phenobarbital resulted in accelerated growth of
preneoplastic focal lesions in C3H and BALB/c mice with
only slight increased growth of preneoplastic lesions in
C57BL/6 mice23.
Alterations in the balance between cell proliferation and
cell death as they impact phenobarbital hepatocarcinogenesis
are influenced by mouse strain.  Maximum induction of
hepatic DNA synthesis in the absence of any evidence of
cytotoxicity in phenobarbital treated 8-week-old B6C3F1
mice is seen in short-term to 28-day studies111.  This is
suggestive of a mitogenic effect.  Furthermore, a dose-
dependent enhanced DNA synthesis and an associated
decreased apoptosis is seen in preneoplastic foci in B6C3F1
mice treated with 100 and 500 mg phenobarbital/kg in the
diet but not 10 mg phenobarbital/kg111,112.  In an initiation-
promotion study in C3H and B3B6F1, cell proliferation was
measured in preneoplastic foci and non-involved
hepatocytes and there was a differentially enhanced response
to phenobarbital in the C3H strain preneoplastic foci113.  The
bromodeoxyuridine labeling index in male C57BL/6J,
B6C3F1 and C3H/HeJ mice initiated neonatally with
diethylnitrosamine followed by phenobarbital promotion for
12 months was positively correlated with focus growth
showing a C3H > C6C3F1 > C56BL/6 strain dependent
effect114.
Murine strain susceptibility to phenobarbital induced
heptocarcinogenesis may also involve alterations in global
DNA methylation as well as methylation associated changes
in oncogene expression.  Both hypomethylation and
hypermethylation can be associated with tumorigenesis115.
While a choline-devoid, methionine-deficient diet causes
global DNA hypomethylation in B6C3F1 and in C57BL
mice, treatment with phenobarbital lowers DNA methylation
in B6C3F1 mice to 20% of control.  Phenobarbital treated
C57BL mice, on the other hand, maintain normal levels of
DNA methylation despite having a higher rate of treatment
induced cell proliferation versus B6C3F1116.  Phenobarbital
treatment of B6C3F1 and the two parental strains is
primarily associated with hypermethylation changes in GC-
rich regions of DNA in the B6C3F1 and C3H mice117 as an
indication that inability to maintain normal methylation is
involved with susceptibility to phenobarbital induced liver
tumors.
Furthermore, B6C3F1 mice on a choline-devoid,
methionine-deficient diet with and without phenobarbital
treatment exhibit increased mRNA expression of Ha-ras and
raf as a consequence of hypomethylation118.  There was
altered global DNA methylation, both hypomethylation and
hypermethylation, in some spontaneous and phenobarbital
induced liver tumors as well as increased Ha-ras
expression118 indicative of a decreased ability of the B6C3F1
mouse to maintain its methylation status.  Following
phenobarbital treatment B6C3F1 mice are also less capable
of maintaining methylation of raf in hepatocytes compared
to C57BL mice119.  However, more phenobarbital induced
than spontaneous liver tumors had increased raf mRNA
levels in contrast to equivalent frequency of enhanced Ha-
ras mRNA levels in both phenobarbital and spontaneous
tumors119 indicating that at least for raf, B6C31 mouse liver
tumors may arise by a separate pathway from spontaneous
tumors.
Examination of the methylation status of Ha-ras, Ki-ras
and myc in spontaneous, chloroform and phenobarbital
induced liver tumors in B6C3F1 mice showed that Ha-rasMaronpot 17
was hypomethylated in all tumors examined, Ki-ras was
hypomethylated in some tumors, and the methylation status
of myc was not changed120,121 indicating that there are some
common biochemical pathways to spontaneous and induced
liver tumorigenesis.
The oncogene mutational profile seen in phenobarbital
induced tumors in both C3H and CF1 mice does not differ
from the oncogene mutational profile in sponataneous
tumors122–124 supporting the contention that phenobarbital
provides a selective growth advantage to heptocytes with
spontaneously occurring mutations.
Very little has been published regarding the
hepatocarcinogenicity of phenobarbital in genetically
engineered mice.  In an initiation-promotion study utilizing 3
different doses of phenobarbital, there was no evidence of
hepatic carcinogenicity in a 26-week study using rasH2 mice
on a BALB/c × C57BL/6 F1 background125.  A 9-month
study of phenobarbital in DNA repair deficient XPA -/- mice
did not yield any tumors126.  There were also no liver tumors
in XPA -/- × p53 +/- and C57BL/6 mice similarly treated
with phenobarbital in the same study.  On the other hand,
phenobarbital decreased tumor latency and increased
multiplicity in livers of c-myc/TGF-alpha mice, primarily as
a consequence of phenobarbital blocking cell death during
initial stages of tumor development127.
Genetics of Murine Liver Tumor Susceptiblity
Although specific murine genes responsible for liver
tumor susceptibility have not been discretely identified,
several loci that influence susceptibility and resistance to
liver tumor induction have been mapped by different
research groups using backcrosses and linkage
analysis47,77,128–131.  These loci influence hepatocyte growth
control, especially in preneoplastic lesions.  The loci and
associated mouse chromosomes implicated in mouse
hepatocarcinogenesis are presented in Table 1.
Susceptiblity to liver tumor induction can vary more
than 50-fold among inbred strains43.  Quantitative
comparison among strain is extremely problematic because
of significant differences in animal models used, study
protocols, choice of carcinogen, age at dosing, and duration
of the observation period.  Attempts to tabulate the liver
tumor incidences and multiplicities along with identification
of all the intended and unintended experimental variables
from 70 years of publications would be non-trivial and
probably not of much help in fostering an understanding of
implications of this target tissue response for human risk
assessment.  Even qualitative statements of relative
sensitivity and susceptibility across decades of studies need
to be carefully considered.  Most scientists will agree that the
C3H male is highly susceptible to liver tumor induction
while the C57BL/6 male is highly resistant.  Based upon
publications of the spontaneous incidences of liver tumors,
the C3H male is intrinsically sensitive to develop liver
tumors as a function of age while liver tumors are extremely
rare in aged C57BL/6 males.  Classifying the remaining
mouse strains with respect to liver tumor susceptibility is
more judgmental but I have attempted to do that in Table 2.
Up to 85% of the greater susceptibility of the C3H
versus the C57BL/6 male mouse to liver tumor induction is
attributable to an Hcs7 (hepatocarcinogenicity sensitivity 7)
locus.  Following a neonatal dose of N-ethyl-N-nitrosourea
or diethylnitrosamine there was a 1.7- to 2-fold acceleration
of the growth rate of preneoplastic foci of cellular alteration
in C3H versus C57BL/6 males without further
treatment20,48,63.  The Hcs7 locus is also associated with a
2.6-fold higher growth rate of normal hepatocytes in C3H
versus C57BL/6 males20.
Partial hepatectomy of 6-week old C3H and C57BL/6
mice treated neonatally with N-ethyl-N-nitrosourea results
in an accelerated growth rate of preneoplastic lesions in the
resistant C57BL/6 mouse but no increase in the already
accelerated growth rate of preneoplastic foci in the C3H
mice24 supporting the contention that the Hcs7 locus has a
role in hepatocyte growth control.  Furthermore, liver tumor
multiplicity was greater than 5-fold increased in C57BL/6
males that underwent partial hepatectomy compared to the
Table 1. Genetic Loci Implicated in Mouse Hepatocarcinogenesis
Locus identifier Mouse chromosome
Hcs7 1
Hcf2 1
Hcs4 2
Hcs5 5
Hcs1 7
Hcs2 8
Hcr2 10
Hcs3 12
Hcf1 17
Hcs6 19
Hcs = Hepatocarcinogen sensitivity.
Hcr = Hepatocarcinogen resistance.
Hcf = Hepatocarcinogenesis female.
Table 2. Relative Susceptibilities of Selected Strains to Liver Tumor
Induction
High susceptibility Intermediate Relatively resistant
susceptibility
C3H C57BR/cdJ BALB/c
CBA FVB C57BL/6
B6C3F1 SM/J C57BL/10
DBA/2 (infant model) P/J 129
Tif:MAGf CE/J DBA/2 (> 5 weeks old)
C3H × CBA LP SWR
CBA × C57BL/10 AKR/J A
C3H × A/J CD-1 IF
DBA/2 × CE/J NMRI RF
LP × 129 A × C57BL/6
LP × DBA/2 C57BL × A
LP × C57BL/10 A × C57BL/10
129 × DBA/2 C57BL/6 × BALB/c18 Mouse Hepatocarcinogenesis
sham controls while there was a 60% reduction in liver
tumor multiplicity in the C3H males that had partial
hepatectomy.  Thus, partial hepatectomy acted as a promoter
for C57BL/6 males but not for C3H males.  Partial
hepatectomy had no effect on foci or tumors in female mice
of either strain.  The data suggest that the physiological
growth stimulus provided by partial hepatectomy as well as
the Hcs7 gene both work through the same growth
regulatory pathway.
It has been demonstrated that both the frequency of
DNA adducts and number of preneoplastic foci of cellular
alteration are similar in C3H and C57BL/6 mice following
treatment with N-ethyl-N-nitrosourea48 and that the
hepatocellular foci take longer to grow to easily detectable
size in C57BL/6 mice20, further supporting the likely role of
the Hcs7 locus in preneoplastic lesion growth control.  The
Hcs7 locus appears to exert its effect at the level of the
hepatocyte since diethylnitrosamine-induced liver tumors
arise exclusively from C3H heptocytes in C3H-C57BL/6
chimeric mice75,132.
Linkage studies of crosses between C3H and C57BL/6
have shown that the Hcs7 C3H allele is sufficient to render
the C57BL/6 susceptible to liver tumor induction with up to
a 14-fold increase in liver tumor multiplicity in congenic
males47.  Furthermore, the tumorigenic effect of the Hcs7
C3H allele is independent of gender, causing an increase in
tumor multiplicity in congenic females as well as males47.
The C57BR/cdJ mouse was originally generated from
the same breeding pair that produced the C57BL/6 mouse11
and paradoxically has a 20-fold greater susceptibility to liver
tumor induction43.  Study of the C57BR/cdJ mouse and
related chimeras has led to identification of several loci in
addition to Hcs7 that are implicated in hepatocarcinogenesis
and account for the enhanced liver tumor susceptiblity of the
C57BR/cdJ versus the closely related C57BL/6 mouse47.
Female C57BR/cdJ are insensitive to inhibitory effects
of estrogen and are unusually susceptible to both
spontaneous and treatment-induced liver neoplasia75.
The high susceptibility is attributable to 2 loci (Hcf1
and Hcf2; located on chromosomes 17 and 1,
respectively).  Using C57BR/cdJ–C57BL/6 chimeras, the
increased susceptibility was found to be intrinsic to the
C57BR/cdJ hepatocytes with over 90% of the tumors in
both male and female originating from these hepatocytes.
This finding provides evidence that the determinants of
hepatocarcinogenesis sensitivity are intrinsic to the specific
hepatocytes.  Further evidence that the determinants are at
the level of the hepatocyte is provided by the early work of
Condamine and co-workers133 using C3H–C57BL/6 and
C3H–BALB/c chimeras to examine the cellular composition
of liver tumors in aged mice as well as by Lee and co-
workers72 in C3H–C57BL/6 chimeras treated neonatally
with diethylnitrosamine.
Multiple genetic loci affecting hepatocarcinogenesis
susceptility and resistance have been identified77,129,130,134
indicating that the genetics underlying susceptibility is
complex.  Using volume percent as a quantitative index of
susceptibility in a study of C3H crosses with A/J and with M.
spretus, Dragani and coworkers concluded that strain
variation in susceptibility to hepatocarcinogenesis involves
polygenic inheritance of unlinked genetic loci128.
While basic strain differences in hepatocarcinogen
sensitivity are determined by intrinsic genetic factors,
studies of C3H–BALB/c sexually chimeric mice treated
neonatally with diethylnitrosamine show that male specific
hormonal or micro-environmental factors are responsible for
promotion of liver cancer in both XX and XY hepatocytes135.
Using recombinant inbred, backcross, and intercross
mouse breeding schemes, researchers at the McArdle
laboratory sought to tease out the genetics responsible
for the biological complexity of hepatocarcinogenicity in
DBA/2 mice.  In the process they identified two
hepatocarcinogenesis resistance genes (Hcr1 and Hcr2) in
the very sensitive neonatally treated DBA/2 mouse77.  Based
on their linkage analysis which covered ~95% of the
genome, it was concluded that neonatally sensitivity DBA/2
mice probably carry multiple hepatocarcinogen sensitive
loci, each with a small effect that in the aggregate overcome
the resistance conferred by Hcr1 and Hcr277.
In most studies examining the susceptibility of different
strains the primary effect is a differential cell proliferative
response in putative preneoplastic altered foci during the
promotional operational phase of hepatocarcinogenesis.
However, in an initiation-promotion study using
diethylnitrosamine initiation after partial hepatectomy of
males at 6 weeks of age followed by phenobarbital,
clofibrate, or ethynyl estradiol promotion, Lee and co-
workers found that interstrain differences in both initiation
and promotion exist23.  BALB/c and C57BL/6 had fewer foci
of altered hepatocytes than C3H after diethylnitrosamine
alone.  Phenobarbital accelerated the growth rate of altered
foci in both C3H and BALB/c and clofibrate increased the
growth of altered foci only in the C3H males.
Mouse strain differential susceptibilities differ between
liver and lung tumors following treatment with agents that
induce neoplasia in both target sites43 indicating that genetic
factors responsible for liver and lung neoplasia are tissue-
specific.
Strain Susceptibility to Spontaneous and Induced
Liver Tumors: Modifying Factors
Cell proliferation, apoptosis, and growth kinetics
Cancer development requires an hereditable alteration
of DNA plus cellular proliferation.  It has been
experimentally shown that cell proliferation is a fundamental
requirement for initiation, promotion, and progression of
spontaneous and treatment induced liver cancer in
mice136,137.  The basis of the preweaning initiation-promotion
model of murine hepatocarcinogenesis is dependent upon
agent induced promutagenic DNA damage being “fixed” by
the enhanced hepatocellular cell proliferation associated
with the rapid liver growth in the neonatal mouse.  For the
adult mouse, the regenerative hepatocellular proliferativeMaronpot 19
response to hepatonecrogenic doses of chloroform138 and
other nongenotoxic agents138–141, or regenerative growth
following partial hepatectomy all serve to initiate the cancer
process.  It has also been postulated that natural infidelity in
DNA maintenance methylation could lead to heritable
hypomethylation that would play a functional role in liver
tumor initiation115,142. Following initiation, liver cancer
promotion requires a proliferative growth advantage for
expansion of initiated clones of hepatocytes143.  During the
process of clonal expansion further genetic alterations may
yield subclones that have enhanced cell proliferative rates
and the ability to progress to malignancy.
There has been considerable study of the relative roles
of cell proliferation versus cell death (apopotosis) in murine
hepatocarcinogenesis, especially for nongenotoxic liver
tumor promoters.  It is generally accepted that the critical
factor driving growth or regression of preneoplastic
hepatocellular lesions in rodents is the balance between cell
proliferation and apoptosis both in the preneoplastic lesions
as well as in the surrounding noninvolved hepatic
parenchyma144.  In a comparison of the roles of apoptosis and
cell proliferation in C3H/He and C57BL/6J mice, it has been
reported that cell proliferation is the prevailing determinant
of liver tumor promotion by phenobarbital and nafenopin in
both strains following diethylnitrosamine initiation145.
While enhanced cell proliferation is not a universal
predictor of liver carcinogenesis146, there is little doubt that it
is an important and necessary component of murine
hepatocarcinogenesis observed for a spectrum of
nongenotoxic agents.  Hepatocarcinogenicity may be driven
either by enhanced cell proliferation and/or reduced
apoptosis within proliferative lesions.  The liver tumor
response in male B6C3F1 mice attributed to dichloroacetic
acid was suggested to involve the ability of dichloroacetic
acid to suppress apoptosis rather than to enhance
proliferation of initiated cells147.  Similarly, suppression of
apoptosis rather than cell proliferation was attributed to
account for the growth of H-ras positive C3H mouse liver
tumors148.  On the other hand, dieldrin promoted focus
growth appears dependent upon cell proliferation and
without effects on apoptosis at multiple concentrations149.  In
general, murine susceptiblity to peroxisome proliferators as
well as other nongenotoxic hepatocarcinogenic agents
correlates more strongly with induction of DNA synthesis
and less so with suppression of apoptosis150.
There is often a concerted effect between cell
proliferation and cell death involving preneoplastic foci of
cellular alteration and noninvolved hepatocytes and this
concerted effect may be influenced by the continuation of
treatment.  For example, in male B6C3F1 mice dieldrin and
phenobarbital increased heptocyte labeling indices and
decreased apoptosis in eosinophilic and basophilic lesions
and both decreased upon cessation of treatment151.
Furthermore, the dose of test agent, for example
phenobarbital, can influence the relative rates of DNA
synthesis and apoptosis with higher doses promoting
outgrowth of focal lesions by increased cell proliferation and
decreased apoptosis112.  In an initiation-promotion study
using C57BL/6, C6C3F1, and C3H males, phenobarbital
promotion following neonatal diethylnitrosamine initiation
resulted in a strain-dependent (C3H>B6C3F1>C57BL)
increase in focus number and size with focus growth rates
positively correlated with cell proliferation and with
intrafocal apoptosis occurring late114.  The authors also
suggested that extrafocal apoptosis was contributory to
clonal growth via removal of adjacent normal cells114.
It is generally accepted that larger proliferative
hepatocellular lesions grow faster than smaller lesions.  In
female B6C3F1 mice initiated with diethylnitrosamine at 12
days of age and subsequently promoted with unleaded
gasoline vapor or dietary ethinyl estradiol, larger
preneoplastic foci in the treated mice had higher hepatocyte
labeling indices152.  In a hepatocarcinogenesis study
involving diethylnitrosamine initiation and phenobarbital
promotion of C3H and C3B6F1 mice, hepatocellular
adenomas had higher bromodeoxyuridine labeling indices
than altered foci with the lowest labeling indices in non-
involved hepatocytes113.  It is noteworthy that the ratio of
labeling index in foci to non-involved hepatocytes rather
than the level of cell proliferation alone was related to the
enhanced liver tumor susceptibility of the C3H mice versus
the C3B6F1 hybrid113.
Preweaning initiation with ethylnitrosourea followed
by a partial hepatectomy as a growth stimulus in C57BL/6J
and C3H/HeJ male mice lead to a tumor volume doubling
time of 2.2 and 2.9 weeks, respectively24.  Following
neonatal initiation with diethylnitrosamine, three strains of
mice were euthanized at 4 intervals up to 42 weeks of age.
The number of liver tumors in C3H mice was 2.5 times that
in B6C3F1 and C57BL/6 but the growth rates were similar
for the 3 strains with a doubling time of 2.1 to 2.5 weeks63.
Larger tumors grew faster63,152 and the tumor periphery grew
faster than the central portions, probably due to a gradient of
oxygen, nutrition, and growth factors.  There were also
differences in tumor growth rates among multiple tumors in
the same mouse.  The growth rate in C57BL/6 liver tumors
was initially fast but subsequently slowed down by 80%.  It
has been suggested that impaired growth of some liver
tumors in C57BL/6 mice is associated with accumulation of
secretory protein cytoplasmic inclusions in tumor cells63.
Different factors may affect hepatoproliferative rates in
various studies.  Using female B6C3F1 mice, the route of
administration can determine whether chloroform enhances
cell proliferation in the liver of B6C3F1 mice81.  Chloroform
given by gavage but not in the drinking water increased cell
proliferation of hepatocytes.  Similarly, the gavage
administration of trihalomethanes, including chloroform,
bromodichloromethane, chlorodibromomethane, and
bromoform, enhanced cell proliferation consistent with their
known hepatocarcinogenicity82.  Dietary restriction of 12-
month old male B6C3F1 mice significantly increased the
rate of hepatocyte apoptosis and significantly decreased the
frequency of proliferating cells compared to ad libitum fed
mice153.20 Mouse Hepatocarcinogenesis
Enzyme induction
Hepatic enzyme induction has been proposed as a mode
of action to explain what is considered a rodent-specific liver
tumor response to treatment with phenobarbital and other
nongenotoxic rodent hepatocarcinogens.  In addition to the
publication by McClain104, this epigenetic mechanism of
hepatocarcinogenesis has been discussed in a 2000
review154.  Generation of reactive oxygen species as a
consequence of futile cycling of P450s155 is capable of
producing tissue necrosis and mutations that would favor
development of hepatic neoplasia.  Reactive oxygen species
can lead to lipid peroxidative damage to hepatocyte cell
membranes and may then cause functional alterations in
membrane receptors that in turn exert liver promoting
action156.  Reactive oxygen species can also modulate gene
expression and lead to altered regulation of growth factors
that favor tumor promotion and progression154.  Temporal
increases in hepatic malondialdehyde, a biomarker of
oxidative damage to lipids, following dieldrin treatment
suggest that oxidative damage may be an early event in
dieldrin-induced mouse hepatocarcinogenesis157.  It has been
proposed that proliferative mouse liver lesions induced
secondary to enzyme induction, such as eosinophilic nodules
seen in phenobarbital treated mice, are phenotypically
different from liver tumors seen in control mice or mice
treated with genotoxic agents and should not be considered a
carcinogenic response directly relevant to the chemical that
caused the enzyme induction158.
DNA methylation and imprinting
In recent years there has been a wider acknowledgement
of the importance and contributory nature of DNA
methylation throughout different stages of cancer
development115,159,160.  Both global and gene specific
alterations involving hypomethylation and hypermethylation
of DNA are significant contributory factors to
oncogenesis160.  DNA methylation is required for
maintaining the status of imprinted genes and for epigenetic
activation of oncogenes and silencing of tumor suppressor
genes.  Temporal analyses of methylation status in mice used
in various hepatocarcinogenesis protocols, particularly in
initiation and promotion studies, provide evidence that
altered methylation is not just a consequence of malignant
transformation but plays a contributory role in liver tumor
genesis.  I hasten to point out that DNA methylation is
involved in a wide variety of biological processes and,
consequently, there is no simple explanation that will cover
the diverse possible ways methylation can impact
oncogenesis.  However, there are definite associations
between DNA methylation, genomic imprinting, and mouse
hepatocarcinogenesis115,160.  Further, DNA methylation is
influenced by dietary levels of methionine97,116,161 and
choline-devoid, methionine deficient induced
hypomethylation is quickly reversed by administration of a
methionine adequate diet162.
The insulin-like growth factor IGF2 and the mannose 6-
phosphate(M6P)/IGF2R receptor genes are known to be
imprinted, have a monoallelic expression in mice, and
provide a possible explanation for enhanced sensitivity of
some mice to liver tumor formation163–165.  It is also of some
relevance that imprinting and alterations in the M6P/IGF2R
gene are associated with human liver tumors166,167 and that
there is loss of IGF2 imprinting in mouse hepatocellular
carcinoma cell lines165.  Genomic imprinting of murine
genes regulated by androgen could also play a role in murine
hepatocarcinogenesis168.  The recent creation of conditional
knock-out mice with tissue-specific inactivation of murine
M6P/IGF2R should prove useful in future studies169.
Oncogenes & tumor suppressor genes
Proto-oncogenes are believed to play an important role
in the genesis of neoplasia when genetically altered or
expressed at increased levels.  In conjunction with several
other genes, growth factors, and transcription regulatory
proteins, proto-oncogenes play pivotal roles in regulating
cell growth, differentiation, and development.  Oncogene
activation associated with mouse liver tumors is both strain
and carcinogen dependent.  Mouse liver tumors involving
several strains document the common observation of
mutations in the H-ras protooncogene170 with the frequency
of H-ras mutations approximately 10-fold higher in
genetically susceptible versus resistant strains171.  For
example, codon 61 point mutations in H-ras in
diethylnitrosamine induced liver tumors occur with a
frequency greater than 50% in C3H mice, 33% in B6C3F1
mice and 0% in C57BL/6 and BALB/c mice171.  Greater
than 50% of spontaneous B6C3F1 and C3H liver tumors
harbor H-ras mutations compared to 7% in BALB/c172.
Analysis of precancerous foci of cellular alteration for
evidence of H-ras mutations has shown that a small
proportion of these foci have H-ras mutations indicating
that this change may be an early and critical event in murine
hepatocarcinogenesis170,171,173.  The frequency of activated
H-ras in induced mouse liver tumors is typically higher for
genotoxic versus nongenotoxic chemicals.  For genotoxic
hepatocarcinogens there is an inverse dose-response
relationship to H-ras activation suggesting that higher doses
may at least partially utilize a non-H-ras pathway for
tumorigenesis170.  The low frequency of H-ras mutations in
tetrafluoroethylene induced mouse liver tumors is indicative
that some mouse liver tumors produced by nongenotoxic
chemicals favor development by a ras-independent
pathway174.  The tumor promoters dieldrin and
phenobarbital increase the frequency of c-Ha-ras wild-type,
but not of c-Ha-ras mutated focal liver lesions in male C3H/
He mice124.  It has been shown that the preferential
outgrowth of proliferative H-ras positive hepatic lesions is
mediated by suppression of apoptosis rather than by
accelerated rates of cell proliferation148.
Other oncogenes can play a role in murine
hepatocarcinogenesis.  C-jun, which has important
functions in cell proliferation and differentiation, is believed
to play a role in hepatogenesis and, by implication, in
hepatocarcinogenesis175.  Increased expression of c-myc asMaronpot 21
well as H-ras has been reported in hyperplastic nodules and
hepatocellular carcinomas in B6C3F1 mice treated with
dichloroacetic acid and trichloroacetic acid176 and increased
expression of c-jun and c-myc in B6C3F1 mice treated with
dichloroacetic acid, trichloroacetic acid and
trichloroethylene84,92.  Hypomethylation of raf has been
associated with enhanced expression of raf in phenobarbital-
induced liver tumors of B6C3F1 mice119.
The ability to identify possible tumor suppressor genes
that are involved with mouse liver tumor development has
been hampered by the relative lack of LOH detection in
murine liver tumors177.  It has been speculated that difficulty
in detecting LOH in murine liver tumors may be a
consequence of the high frequency of tetraploidy in mouse
hepatocytes178.  However, since hypermethylation silencing
of tumor suppressor genes is known to occur179, this
epigenetic mechanism could be involved in murine
hepatocarcinogenesis.  In addition to altered expression of
proto-oncogenes and tumor suppressor genes, mutations and
perturbations in other genes such as beta-catenin, E-
cadherin, cyclin D1, and EGFR have been documented in
mouse liver tumors180,181.
Hormones
With the exception of the female C57BR/cdJ mouse,
both spontaneously occurring and treatment induced
hepatocellular tumors occur with significantly greater
frequency and multiplicity in males than in females19,58,65,182.
Castration of 2-day old BALB/c mice followed by
gavage administration of N-2-fluorenylacetamide starting at
one week of age completely abolished development of
hepatocellular carcinomas183.  Using orchidectomy and
ovaiectomy alone as well as with and without subsequent
administration of androgens and ovarian hormones or simply
administration of hormone without ablative surgery, several
studies have shown that testosterone promotes and ovarian
hormones suppress development of liver tumors in
mice43,70,73,182,184–186.  As an indication of the magnitude of
the hormonal effect, neonatal urethane exposure followed by
castration or ovariectomy at 6 weeks of age resulted in a 96%
and 20% incidence of heptomas in sham-operated male and
female B6C3F1 hybrids, respectively, while orchidectomy
and ovariectomy hybrids had hepatoma incidences of 62%
and 67%, respectively187.  Using C3H–BALB/c sexually
chimeric mice, Tsukamoto and co-workers show that while
basic strain differences are genetically determined, male
hormonal or micro-environmental factors lead to promotion
of liver cancer in both XX and XY hepatocytes135.
C57BL/6 × DS F1 mice injected at 18 days of age with
3’-methyl-4-dimethylaminoazobenzene and castrated at 23
days of age had a reduced multiplicity of adenomatous
hepatic nodules but castration did not influence the incidence
of either adenomatous nodules or carcinomas in males.
Ovariectomy of females shortened the latency and increased
both the incidence and multiplicity of adenomatous
nodules186.
Endogenous liver tumor promotion of preneoplastic
foci of altered hepatocytes by testosterone is considered a
primary explanation for the well documented increased
susceptibility of male versus female mice21,70.  The tumor
promoting effects of testosterone are mediated by the
hepatocyte androgen receptor43.  Castration of male mice
leads to a 3-fold increase in hepatocyte androgen receptors, a
result that approximates the androgen receptor levels in
female mouse hepatocytes43.
The greater susceptibility to induction of liver neoplasia
in male versus female mice associated with testosterone is
attributed to its positive effect on the growth rate of
preneoplastic foci of cellular alteration21,55,70,188.  Either
castration of male mice or administration of testosterone to
female mice results in a decreased or increased growth rate
of preneoplastic lesions, respectively, as well as a
corresponding alteration in the multiplicity of liver
tumors21,182.  Suprisingly, however, the actual testosterone
levels among susceptible and resistant inbred mouse strains
is not correlated with liver tumor susceptibility43.  Similarly,
the degree of binding of testosterone to hepatocellular
androgen receptor is not correlated with the differential liver
tumor susceptibility among mouse strains43.
In investigating the role of growth hormone in
mediating the effects of sex hormones on liver tumor
development, investigators at the McArdle lab treated
growth hormone deficient C57BL/6J lit/lit mice neonatally
with diethylnitrosamine184.  There was up to a 59-fold
increase in tumors in the growth hormone deficient mice
versus the wild type C57BL/6J with the effect significantly
more dramatic in males than in females.  These investigators
then bred the growth hormone deficiency onto a C57BR/cdJ
and a C3H/HeJ background and demonstrated that growth
hormone deficiency suppressed liver tumor development to
less than 1%184.  The authors conclude that growth hormone
is a potent endogenous regulator of susceptibility and its
absence abrogates the effects of sex hormones and genetic
background on liver tumor susceptibility.
Diet and body weight
It has long been know that natural vs synthetic vs semi-
synthetic diet plus caloric intake, amino acid composition,
lipid content, methyl deficiency, etc. impact safety
assessment and hazard identification rodent toxicity and
cancer studies189,190.  Hancock and Dickie reported 100%
incidence of hepatoma in D2CEF1 and CED2F1 hybrids at 8
to 14 months of age when switched to a high protein, high fat
diet whereas for the previous 16 years neither hybrid had
liver tumors even at 28 to 32 months of age191.
In an effort to better control growth, body weight, and
age-related disease including tumor incidence, the National
Toxicology Program changed from NIH-07 diet to a new
diet designated NTP-2000.  By reducing the caloric content,
mainly by increasing fiber content and reducing protein, the
diet could be fed ad libitum.  NTP-2000 proved beneficial
for a number of variables and, importantly, lowered body
weight and the spontaneous incidence of liver tumors in
male B6C3F1 mice192.  An alternative approach of utilizing22 Mouse Hepatocarcinogenesis
dietary restriction has been championed by the FDA’s
National Center for Toxicologic Research as a means to
minimize tumor and survival variability within and between
studies193–195 and has been shown to inhibit spontaneous and
treatment-induced tumorigenesis189,193.  A rather extreme
dietary restriction of 60% led to increased survival in male
and female B6C3F1 mice and resulted in an 8.6-fold reduced
liver tumor incidence in control B6C3F1 mice196.  Dietary
restriction started as late as 3 months after treatment with a
potent hepatocarcinogen can still have an inhibitory effect on
mouse liver tumor development197.
There is a strong correlation between body weight at 52
weeks and the subsequent incidence of liver tumors in
control B6C3F1 mice193,198,199 and a concern that body
weight differences between dosed and control groups could
mask carcinogenic effects sensitive to body weight
changes197,198.  Consequently, reduction of body weight gain
would be expected to reduce the spontaneous liver tumor
burden.  Using tumor risk data from several hundred
B6C3F1 mice, Leakey and coworkers constructed body
weight weight curves to predict the amount of dietary
restriction required to predict a 15 to 20% spontaneous liver
tumor incidence194.  In a chloral hydrate bioassay using this
approach, they were successful in achieving their objective
and, in addition, the variable feed restriction paradigm
provided for a statistically significant dose-response in their
study versus the ad libitum treated cohort200.  As further
testimony to the importance of diet, it has been shown that
the post-weaning diet in C57BL/6J × Cast/EiJ F1 mice can
affect IGFII methylation and lead to permanently decreased
IGFII expression via imprinting201.
Cell-cell communication
Multiple in vitro and in vivo experimental studies have
shown that fully functional gap junctions inhibit both
spontaneous and treatment induced neoplasia and that a
number of nongenotoxic rodent carcinogens inhibit gap
junction cell-cell communication, leading to enhanced
cellular proliferation and increased neoplasia201–205.  Gap
junction cell-cell communication is controlled by connexins
which constitute a family of tumor suppressor genes203.
For the most part, studies of gap junction intercellular
communication in hepatocytes have been carried out on
primary cultures.  Using primary B6C3F1 hepatocytes, it has
been demonstrated that endosulfan and at least one
endosulfan metabolite, plus chlordane and heptachlor inhibit
gap junctional communication in a dose dependent
manner206.  A dose dependent inhibition of gap junctional
cell-cell communication in primary mouse hepatocytes has
also been shown for phenoparbital, DDT, and lindane and is
most probably mediated via cAMP207,208.  Similar inhibition
has been documented in primary mouse hepatocytes for
monoethylhexylphthalate, tricholoracetic acid,
trichloroethylene, nafenopin, and arochlor 1254207.
Studies of liver tumor promotion in rats using
phenobarbital, polychlorinated biphenyl, and
dichlorodiphenyltrichloroethane showed an increase
hepatocellular proliferation and decreased gap junction
cellular communication, albeit without a quantitative
association209.
Cell-cell communication can play an important role in
mouse hepatocarcinogenesis.  Mice deficient in connexin32,
the major gap junction protein expressed in hepatocytes, had
a 25- and 8-fold increase in spontaneous liver tumors in male
and females, respectively, compared to wild-type controls202.
These same authors showed an increased incidence of liver
tumors and a faster growth rate of these tumors in
connexin32 deficient mice on a C57BL/6/129/Sv-F1
background compared to controls one year after neonatal
treatment with diethylnitrosamine202.
While both oncogenes and growth factors have been
shown to downregulate gap junctional function and analysis
and both rat and mouse hepatic neoplasms have altered gap
junctional cell communication207, the exact role of cell-cell
communication in the sequential development of mouse
hepatocarcinogenesis is unclear.  However,
hypermethylation inactivates connexin genes210, suggesting
that methylation may contribute to carcinogenesis by
disruption of gap junctional intercellular communication.
Viral infection
A retrospective review of over 30 control groups and
over 30 low dose and high dose groups of B6C3F1 mice of
each sex was undertaken to determine the effect of viral
infection on tumor incidence in conventional cancer
bioassays211.  Sendai virus infection was associated with
increased incidence of liver tumors and lympomas in
B6C3F1 males but no increase of tumors in female B6C3F1
mice.  The increased tumor response may be a consequence
of higher survival of control, low-does and high-dose
groups211.
Reversibility (Conditional Hepatocarcinogens)
It is certainly well documented that a major hallmark of
liver tumor promotion by nongenotoxic rodent
hepatocarcinogens is the regression of preneoplastic foci and
nodules following cessation of treatment151,212,213.  A
dramatic example of the extent of this process is the
regression of 30% of chlordane induced hepatocellular
adenomas and carcinomas within a few weeks after stopping
treatment214.  Regression of frank liver neoplasia has been
reported in humans following cessation of growth hormone
supplements containing androgens215,216, in women after
ceasing use of oral contraceptives217,218, and in rats after
cessation of nafenopin212, phenobarbital and clofibrate219,
and the peroxisome proliferators WY-14,643220.  Agents
which require continual administration for the stable
presence and growth of preneoplastic and neoplastic rodent
liver lesions are probably best categorized as conditional
hepatocarcinogens.Maronpot 23
Historical Controls
For assessment of liver tumor data in cancer bioassays,
laboratory specific historical control data are extremely
valuable in putting unusual high or low tumor responses into
perspective198,221,222.  Acquiring accurate historical control
data for liver tumors of different inbred mouse strains is
problematic because of a host of variables such as caging,
diet, individual study duration, route of test article
administration, and the period of time over which the control
data are acquired.  The best data come from labs with
consistent study protocols and with periodic updating of a
moving window of observation to generate the most relevant
contemporary historical control information.  While
historical control data from organizations such as the
National Toxicology Program and the FDA National Center
for Toxicological Research are readily available, similar data
from industrial organizations is generally not available to the
public.  Based on extraction of concurrent control data from
published reports, some crude estimates could be generated
but these would constitute isolated examples of concurrent
controls rather than solidly reliable historical controls.
Based on web site data for March 2007, the NTP mean (±
SD) historical control data for B6C3F1 mouse liver tumors
with all routes combined and using NTP-2000 diet is shown
in Table 3.
Some comparative historical data extracted from the
NTP Workshop on liver tumors in different mice but without
background husbandry and study duration data223 are
presented in Table 4.  There are dramatic strain and stock
differences in liver tumor incidences and, based on data in
Tables 3 and 4, the NTP B6C3F1 mouse has a particularly
high and variable background incidence of liver tumors.
Rationale for Selection of Experimental Mice
Strain and stock selection of experimental mice for
toxicity and carcinogenicity studies is based partly on ready
accessibility, organizational history, and the specific
purposes of the study.  Unfortunately, the reasons for
selection of specific mice for cancer bioassays are often
obscure.  However, once selected for use in hazard
identification screening, there are two primary reasons for
the continued use of the particular strain: (1) reluctance to
lose the historic control database, and (2) historic inertia.  In
the early phases of the National Cancer Institute cancer
bioassay program several mouse strains including HaM/
ICR, CD-1, and strain A were used224,225.  The report of a
large scale study involving 20,000 mice exposed to 127
different pesticides and industrial chemicals compared
responses from two F1 hybrids: (C57BL/6 × C3H/Anf) F1
and C57BL/6 × AKR)F116.  The B6C3F1 hybrid was more
effective at identifying the chemicals that were considered
known carcinogens and, as a result, it ultimately became the
default mouse for the National Cancer Institute cancer
bioassay program.  Use of this hybrid has continued with the
transfer of the bioassay program to the National Toxicology
Program.
A recent National Toxicology Program workshop was
held to consider the most appropriate rodent strains for
hazard identification studies223 and, although there was
considerable discussion considering mouse strains other than
the B6C3F1, a decision to change has not been forthcoming.
The contemporary National Toxicology Program philosophy
would consider use of either additional or alternative mouse
strains for specific studies on a knowledge-based approach
to testing and based on specific issues related to the agent
under study.  There was general interest, however, in
considering use of multiple isogenic mouse strains,
especially if appropriate background information were
available and in spite of potential logistical constraints223.
The outbred CD1 and NMRI stocks and inbred C57BL/
10 mice are generally favored for carcinogenicity studies by
the pharmaceutical, pesticide, and agrochemical
communities103.  A comfort level in use of these particular
mice plus a robust historical control database are reasons
these organizations maintain use of their preferred mouse.
Evaluation, Interpretation, and Relevance
General
As a separate exercise from assessing the relevancy of a
positive or negative cancer bioassay response, it must first be
determined if the response observed in the test animals is
Table 3. Historical Control Incidences (% ± SD) in National
Toxicology Program B6C3F1 Mice as of March 2007
Male Female
H. Adenoma 43.31 ± 14.15 25.84 ± 15.77
H. Carcinoma 25.99 ± 9.10 10.19 ± 6.55
H. adenoma or H. carcinoma 59.57 ± 15.36 32.44 ± 17.45
All routes of administration are combined.
Animals were fed NTP-2000 diet.
For the hepatocellular adenoma or hepatocellular carcinoma category the
range in males was 20–85% based on 29 studies and the range in females
was 8–62% based on 31 studies.
Data obtained from http://ntp.niehs.nih.gov
Table 4. Benign and Malignant Liver Tumor Incidences (%) in
Control Mice
Male Female
Strain Liver Liver Liver Liver
Benign Malignant  Benign Malignant
B6C3F1 (NTP) 32.5 22.8 20.1 8.3
B6C3F1 (NCTR) 18.6 9.6 4.6 1.1
CD-1 (Proprietary 1) 10.8 10 1.5 1
CD-1 (Proprietary 2) 10.1 6.7 2.2 0.9
C57BL/10J 0.4 0.4 0.2 0.2
Data extracted from King-Herbert & Thayer223. NTP = National
Toxicology Program.  NCTR = National Center for Toxicological
Research.24 Mouse Hepatocarcinogenesis
credible.  A negative cancer outcome in both sexes of two
test species is generally interpreted to reflect the probability
that the agent under test is not a potential human carcinogen.
This judgment is not made in a vacuum but rather takes into
account many other factors including whether the agent is
genotoxic, the toxicokinetics in the bioassay models,
evidence of a biological response indicative of adequate
exposure, sufficient survival for the duration of the bioassay,
etc.  Given that all factors favorably support the bioassay
outcome, it is probable that existing or pending regulatory
actions will be mitigated.  However, it is readily understood
that one can never prove a negative; susceptible human
subpopulations or individuals might react unfavorably to
agent exposure; and the bioassay outcome could be
reflective of a false negative response226.
Multi-site and trans-species carcinogens
Positive cancer responses in the bioassay test species
engender a spectrum of interpretative response and
sometimes a considerable degree of controversy.  This
follows from the fact that bioassays yield varying degrees of
response.  At one end of the spectrum is the clear response in
which multiple cancers occur early in the study involving
multiple tissues in both male and female rats and mice – a
multi-site, trans-species rodent carcinogen.  At the other end
of the spectrum of response is the situation where there is a
marginal increase in a common spontaneous tumor and the
response is seen in one sex of one species and typically only
at the highest dose.  For those individuals who subscribe to a
conservative public health policy, these responses are often
considered indicative of potential human risk for developing
cancer, at the very least for susceptible human
subpopulations or in situations where there may be in utero
human exposure.  The majority of positive outcomes, which
in the case of the National Toxicology Program represents
approximately 50% of agents tested, fall between the
extremes of response and are generally classified as showing
either clear or some evidence of carcinogenicity.
Appropriate regulatory agencies and bodies then take the
bioassay outcome into account as one of the factors in the
weight of evidence for determining the potential human
health hazard.  Multi-site and trans-species carcinogens
would provide more compelling justification for protective
regulatory decisions than a single sex, single species
marginal response.  Situations where there is an equivocal
response ideally require additional, and perhaps more
rigorous, studies; but cost considerations generally preclude
additional studies except in unusual circumstances.
Mouse liver carcinogens
Concern about a mouse liver tumor response comes
about in situations where it is the sole response in a two-
species carcinogenicity study, is typically seen in liver tumor
susceptible strains when given high doses of nongenotoxic
agents, when the likely human exposure is significantly
lower than bioassay responsive doses, when the likely mode
of action is expected to have a threshold, and when the mode
of action is not relevant to humans.  Given what we have
learned from various bioassay toxicity and carcinogenicity
databases generated over the past 40 years, short and
medium term exposures can reasonably be expected to
identify predictive rodent- and chemical-specific biomarkers
and, thus, to establish predictive testing strategies227,228.  This
may be relatively easy for prediction of liver responses by
use of clinical chemisty, organ weight, histopathology, and
cell proliferation measurements and should work equally
well for rats as well as mice.
Mouse debate
Over the last three decades and especially during the
last few years, there has been considerable concern and
debate regarding the utility of the mouse for long-term
rodent carcinogenicity testing9,229–234.  A few quotes (without
attribution) serve to illustrate one position regarding the
utility of mouse bioassays:
“It is not appropriate to make human risk
assessment decisions based on a mouse liver tumor
response”
“.... it is suggested that strong consideration be
given to deleting the mouse as a routine test animal
....”
“So, my conclusion is, in the future, probably the
near future, with sufficient scientific evidence
added, we can eliminate the long-term mouse
bioassay from our protocol.”
“For non-genotoxic hepatic tumor promoters, the
weight of the evidence would indicate that a
mouse liver tumor response is not a relevant
indication of human cancer risk.”
“.... have strengthened my views that from a
regulatory standpoint the use of mouse strains with
a high spontaneous incidence of hepatic tumours
for routine carcinogenicity testing is undesirable.”
“The utility of the mouse for purposes of routine
screening of chemicals for carcinogenic potential
is, therefore, highly questionable.”
A primary basis for recommendations that the mouse no
longer be used for carcinogen hazard identification stems
from the liver tumor response.  Some argue that, at least for
pharmaceuticals, the mouse cancer bioassay is redundant in
that it has not provided evidence of carcinogenicity that was
not already identified in the rat cancer bioassay9,235.  The
proponents of using the mouse bioassay are concerned that
dropping it from the armamentarium will preclude the
possibility of identify trans-species carcinogens223,232,236–238.
The current development of new genetically engineered
mouse models to better understand and combat cancer and
ongoing efforts to map the genome of multiple inbred mouse
strains10 suggest that it would be prudent to retain the mouse
as a cancer bioassay species.  Although the debate regarding
the utility of the mouse as a cancer bioassay model will
probably continue, it appears that mice will retain a role in
understanding the complexity of cancer as a disease,
identifying causative factors, serving as a screening modelMaronpot 25
for hazard identification, and providing a basis for therapy
and, hopefully, prevention.
Relevance
Of all the concerns and controversies surrounding
rodent cancer bioassay programs, relevance to potential
human disease is of critical importance.  Since the objective
of the rodent cancer bioassay is to provide information that
will permit the avoidance, reduction, and prevention of
carcinogenic risk to humans, the relevance of the bioassay
must be defined.  Not surprisingly, there are two schools of
thought on this topic228,239–245.  It is generally accepted that
agents whose mode of action involves direct interaction with
and alteration of DNA should be considered to have human
carcinogenic potential.  These DNA reactive agents are
typically considered to not have a threshold, although there
may be some low level of exposure to genotoxic agents that
simply will not result in cancer in a human lifetime.  The
majority of agents tested in contemporary rodent cancer
bioassays, however, are non-genotoxic and, if they indeed do
lead to cancer in rats and/or mice, the mechanism by which
that rodent cancer occurs should ideally have relevance to
humans.  Over the years, diligent investigative work
subsequent to observed cancer responses in the rodent
bioassay, has provided convincing evidence that some
bioassay cancer response are rodent-specific and simply not
germane to humans. Agencies have tended to mitigate
regulatory decisions when clear rodent-specific mode of
action data are provided and all other factors are considered,
including a cost-benefit analysis246,247.
The Future
The rodent cancer bioassay is unlikely to be abandoned
in the near future.  Even given an appealing alternative for
identifying carcinogenic hazard, just the process of
validating that alternative and overcoming historical inertia
could easily take several years.  Furthermore, the rodent
cancer bioassay has evolved to address various toxicities
other than just cancer.  Concerns about reproductive toxicity,
neurotoxicity, immunotoxicity, and developmental effects
have captured public awareness and organizations are
increasingly addressing the issue of toxicity and other non-
cancer consequences for human health.
Contemporary rodent bioassay design frequently
incorporates sub-studies for the generation of information
about mode of action.  Concerns about the sensitivity of the
rodent bioassay and growing concern about long-term and
trans-generational human health issues are leading to the
prospect of running bioassays that commence with in utero
exposure followed by continuation of exposure during
nursing and following weaning.  This development will pose
considerable logistical considerations for testing as well as
being resource intensive.  The general belief is that in utero
exposures will provide a more sensitive bioassay animal
model.  Its use will undoubtedly identify more agents as
hazards, including cancer hazards.  If such studies are
undertaken they will hopefully be designed to
simultaneously develop predictive biomarkers to help
obviate the need for continual long-term resource intensive
testing.
While the majority of bioassays have been carried out
on single specific agents in the workplace and general
environment, there is a growing interest in understanding the
health consequences for the total environmental load of
exposures and in testing relevant mixtures of agents that
would likely reflect realistic human exposures.  Examples
include complex non-standardized agents such as readily
available over-the-counter herbal medicines, combinations
of exposures from water disinfection byproducts, physical
exposures from electromagnetic fields and cell phones,
nanoscale materials, and endocrine disruptors to name a few.
This type of testing will require novel exposure scenarios
and will create logistical hurdles and new issues of
interpretation and relevance.  The problems will be all the
more complex as the rodent bioassay is expanded to include
non-cancer endpoints, exploration of interacting modes of
action, and identification of biomarkers of exposure and
effect that might have applicability in protecting human
health.
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